25/01/2010 (Agence Europe) - On Monday 25 January, the European Commission granted clearance to the acquisition of joint control of Archimedes Pharma Ltd (Archimedes) of the UK through a shares buy-out by Warburg Pincus Private Equity VIII OP and Warburg Pincus International Partners LP, controlled by Warburg Pincus & Co of the US, and Novo Nordisk A/S and Novozymes A/S, owned by the Novo Nordisk Foundation (Novo) of Denmark. Warburg Pincus is a US based global private equity investor with investments focused on a range of sectors, including healthcare. Novo supports research in health science and art history primarily through the award of grants. Archimedes is a hospital-focused specialty pharmaceutical group with established commercial operations and a portfolio of products focused on oncology, pain, neurology and critical care. (O.L./transl.fl)